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Active pharmaceutical ingredients (API) are most frequently
administered in oral formulations which must demonstrate
an acceptable degree of palatability in addition to the obvious
therapeutic value. Oral drug delivery constitutes 70 to 80
percent of the drug delivery market and tablets and capsules,
in existence since the nineteenth century, are the most frequently
used solid dosage formulations. The drug substance’s
physicochemical characteristics, the manufacturing method
and the excipients added to the formulations all contribute
to ensuring therapeutic activity. Many APIs, however, have
a bitter, disagreeable taste and may also have an unpleasant
odour so whenever drug administration requires the patient
to taste the drug, palatability becomes a critical factor in
driving patient compliance, prescribing practices, the perceived
quality of the drug product, and ultimately its success. Within
the pharmaceutical industry, taste masking techniques are
employed to prevent the drug substance exhibiting a bitter
or unpleasant taste. This is especially relevant in the paediatric
market as drug products are typically chosen on the basis
of texture, taste and ease of use. Poor organoleptic properties
will have a negative influence on paediatric compliance.
Palatability can also play an important factor in a product’s
perceived quality and in differentiating products in the market.
Many taste-masked products are dispensed in oral formulations
such as tablets and capsules but also gels, syrups, solutions,
emulsions, lozenges and films. In addition to the taste concerns,
the formulation needs to survive the high temperatures, high
moisture and/or high pressure treatment which may be
encountered during processing, and, once manufactured,
appropriate storage conditions need to be defined. Striking
a balance between attaining palatability by masking undesirable
tastes and imparting a pleasant flavour and mouth feel, all
within the context of an effective, stable dosage form, presents
a unique formulation challenge. The more pleasurable the
taste, the more opportunity for abuse or accidental overdosing
especially with respect to paediatric
formulations, therefore the aim is for
somewhere between not being attractive,
and not feeling unpleasant taking the
medicine. Regardless of the flavour
system used, the challenge is how to
deliver unpleasant compounds, usually
the API, while maintaining patient
acceptability, efficacy and compliance.
There are two strategies used in order
to reduce the detrimental effects of a
bitter-tasting drug: either to cover the
bitter taste by administering
simultaneously some very intense
flavour to ‘mask’ the bitter taste (flavour
enhancers) or to prevent the contact
between drug and the taste receptors.
Using flavour enhancers is the simplest approach for taste-
masking, especially for liquid formulations but is not particularly
useful for very bitter, water-soluble drugs (1). The primary
taste-masking excipients used in pharmaceutical formulation
are sweeteners, flavouring agents and amino acids. In
addition to palatability, the chosen enhancer has to be
compatible with the other excipients added to the formulation
to add processing or to ensure bioavailability and will be
different for each active and each formulation. Chemical
modification, including prodrug design or selection of a
lipophilic counter-ion, is an effective method for reducing
solubility, and thereby improving taste. The pH of a formulation
can also be manipulated to reduce drug solubility and
lipophilic vehicles such as lecithins can also be employed to
coat the buccal cavity (including the taste buds) and reduce
the flavour threshold of bitter tasting molecules. Similarly,
common technologies involving applying coating layers of
hydrophilic polymers, such as celluloses, provide one of the
most straightforward approaches to taste masking. The
coating, along with additional flavours, if required, can be
applied to the whole tablet or to particulate material prior
to compression into tablets. Recent innovations include the
use of gelatine and non-animal derived coatings for tablets
that are tamper-evident and can be designed with different
colours for branding purposes. They are reported to be
preferred by patients due to their ease of swallowing and
superior taste- and odour-masking properties (2, 3). Bitter
tasting granules can be coated with water-soluble polymers
of hydroxypropyl methylcellulose and sugars such as sucrose
and lactose to decrease the bitter perception at the time of
administration (1). Coating drug particles with appropriate
polymers will improve the taste but will also modulate release
and improve stability. Prolamines, extracted from ceral grains
and flour, such as zein, gliadin and hordein can also be
used and the resultant masking is effective over a prolonged
storage period without reducing onset
of action or bioavailability (1).
Recent progress in taste masking
technologies has enabled development
of novel dosage forms such as fast
dissolving tablets, fast dissolving films
and chewable tablets. Oral dispersible
tablets (ODTs), for example, are designed
to disintegrate and/or dissolve rapidly
in the saliva without the need for water,
within seconds to minutes. They are
therefore convenient and may have
an altered absorption profile resulting
in a faster onset of action.
Microencapsulation and complexation
with ion-exchange resins or cyclodextrins
can be used along with other flavours
Table 1. Advantages of microencapsulation for
drug delivery.
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and sweeteners for taste-masking of
bitter drugs in these formulations.
Taste masking is very often an essential
feature of ODTs and can also be the
rate-determining mechanism for
dissolution/release. s. Cyclodextrins
(CDs) are cyclic oligosaccharides
derived from starch containing six
(αCD), seven (βCD), eight (γCD),
nine (δCD), ten (εCD) or more (α-
1,4)-linked α -d-glucopyranose units. Beta-cyclodextrin is
the most widely used complexing agent for inclusion type
complexes and is suitable for use with potent substances (4).
Ion-exchange resins are high molecular weight polymers
with cationic and anionic functional groups used in drug
formulations to mask taste and these agents can also can
stabilize the sensitive components, sustain release of the
drug and aid disintegration. Drugs are attached to the
oppositely charged resin substrate, forming insoluble adsorbates
or resonates, through weak ionic bonding so that dissociation
of the drug-resin complex does not occur under the salivary
pH conditions thus masking unpleasant tastes or flavours.
Microencapsulation is a method of wrapping small entities
in individual coatings designed to protect, separate or aid
in storage. Controlled-release microparticulate dosage forms
offer a number of distinct advantages over many conventional
dosage forms and the technique has numerous applications
for pharmaceuticals in addition to taste masking (Table 1).
It can be used to protect labile constituents from degradation
or to allow combination of incompatible ingredients. Polymers
used can be natural or synthetic, and typical polymers used
for miroencapsulation of pharmaceuticals are polypeptides
and proteins, such as albumin, and gelatine and polysaccharides,
such as starch and chitosan. Synthetic polymers that have
been used successfully in marketed products are polylactide
(PLA) and polylactide-co-glycolide (PLGA) and polyanhydrides. 
Two main types of encapsulated systems are prepared,
microcapsules or microspheres. In microspheres, the drug
is distributed throughout the polymer matrix and thus must
dissolve, melt or erode to provide drug release. The polymers
used will often biodegrade within the body, thuds eliminating
the need for removal after release. Coating of microparticles,
or formation of a shell surrounding the drug, results in the
formation of microcapsules and normally the drug will diffuse
slowly across the membrane. The rupture of the outer polymeric
membrane will provide release of drug. Different triggers
can be used to initiate release of the encapsulated product
such as pH changes, time, enzymatic activity or osmotic
forces. 
Frequently used encapsulation techniques include spray-
drying, coacervation and phase separation, interfacial
polymerization and extrusion and conditions can be varied
to control the rate of release of active ingredient (Figure 1).
Extrusion microencapsulation has been used is useful for the
encapsulation of volatile and unstable flavours in glassy
carbohydrate matrices, although the particles do tend to be
larger than those made by corresponding methods (5).
Up to recent times, the most widely used method for measuring
the taste characteristics of pharmaceutical preparations were
in vivo approaches including human taste panel studies,
electrophysiological methods and even animal preference
studies (6). Within the pharmaceutical industry, biomimetic
taste sensing systems (BMTSSs), such as multichannel taste
sensors or electronic tongues with global selectivity, have
been adopted and the further acceptance of these emerging
in vitro approaches for assessing taste characteristics of taste
masked drug and drug products will result in a decreased
reliance on human panel tests. Electronic sensing instruments
such as an electronic nose and tongue can quantify, qualify
and compare chemical properties of both the raw materials
(flavours, excipients or APIs) prior to
formulation and various formulations
according to their origins, qualities,
shelf life or stability, reactions during
aging under various storage conditions
or packaging (7). Such technologies
require minimal sample preparation
and can objectively and safely
characterize many chemical properties
of ingredients and formulations. They
enable screening of a larger library of ingredients, additives
or taste screening of formulation candidates to speed up
and optimise the formulation process development, especially
for pharmaceutical formulations that cannot be safely tasted
by a human panel. This has benefits for development time,
development costs, subjectivity, bias, and safety concerns
(8). These techniques can also be used to assay the flavour
concentration during release testing of formulations and to
monitor flavour shelf-life in the marketed container. They
can also be implemented for selection of appropriate packaging
for the formulation in order to ensure the flavour shelf-life
(9). In vitro approaches to study taste are useful in the
development of effective taste-masking procedures and the
development of palatable formulations but will also be useful
in high-throughput taste assessment for testing of flavour
release. Encapsulation technology from the pharmaceutical
industry can be used to entrap sensitive ingredients, such
as volatile and labile flavours, into solid carriers to increase
their protection, reduce evaporation, promote easier handling,
and control their release during storage and application. In
addition to preventing degradation of the agents, the
encapsulation may provide controlled release, leading to a
different pattern of flavour release, e.g. delayed onset or
pulsatile delivery. The controlled release of ingredients at
the right place and the right time can improve their effectiveness.
As modern perfumes include components blended to produce
a combination of scents designed to last for several hours
and provide a combination of notes the ability to control the
rate of release of the lingering notes will be an advantage. 
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Figure 1. PLGA microspheres formed using a double
emulsion solvent evaporation method.
